TRAP trial: ADI-PEG20 in combination with pemetrexed and cisplatin
Researchers have been involved in a study looking at the drug ADI-PEG20 in combination with pemetrexed and cisplatin in treating cancer that has spread to another part of the body or into a high grade brain tumour.
Lead by Dr Peter Szlosarek at the Barts and Brighton ECMC, the TRAP study is looking at the effect of the amino acid, arginine (which promotes cell growth), on the cancer cells. The drug ADI-PEG 20 binds with arginine, lowering its concertation in the body. Researchers are subsequently studing whether this has an impact in delaying the growth of cancer cells.
This innovative Phase I trial has now progressed into a Phase II/III study. The Phase I of the trial was to ensure the highest safe dose of the drug, to give in combination with pemetrexed and cisplatin. The second part of the trial, which will ensue shortly, will look at how well the allocated dosage will work on people with non-small cell lung cancer, mesothelioma in the chest, melanoma of the eye, or high grade glioma.
For more information, click here.